Panagora Asset Management Inc. Has $2.63 Million Stock Position in MacroGenics, Inc. (NASDAQ:MGNX)

Panagora Asset Management Inc. grew its stake in shares of MacroGenics, Inc. (NASDAQ:MGNXGet Rating) by 54.3% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 163,620 shares of the biopharmaceutical company’s stock after purchasing an additional 57,573 shares during the quarter. Panagora Asset Management Inc. owned about 0.27% of MacroGenics worth $2,626,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in MGNX. Bellevue Group AG boosted its stake in shares of MacroGenics by 15.8% in the third quarter. Bellevue Group AG now owns 8,544,597 shares of the biopharmaceutical company’s stock valued at $178,924,000 after buying an additional 1,168,571 shares during the period. Wasatch Advisors Inc. lifted its stake in MacroGenics by 4.9% during the third quarter. Wasatch Advisors Inc. now owns 4,319,051 shares of the biopharmaceutical company’s stock worth $90,441,000 after purchasing an additional 201,534 shares during the last quarter. RTW Investments LP boosted its holdings in shares of MacroGenics by 56.1% in the 3rd quarter. RTW Investments LP now owns 3,975,554 shares of the biopharmaceutical company’s stock valued at $83,248,000 after purchasing an additional 1,428,629 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of MacroGenics by 1.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,235,876 shares of the biopharmaceutical company’s stock valued at $19,836,000 after purchasing an additional 18,792 shares during the last quarter. Finally, Point72 Asset Management L.P. raised its holdings in shares of MacroGenics by 113.9% during the 3rd quarter. Point72 Asset Management L.P. now owns 883,461 shares of the biopharmaceutical company’s stock worth $18,500,000 after buying an additional 470,361 shares in the last quarter.

MGNX stock opened at $4.16 on Friday. The company’s fifty day simple moving average is $7.95 and its 200 day simple moving average is $12.70. MacroGenics, Inc. has a 12-month low of $3.96 and a 12-month high of $32.81. The firm has a market cap of $255.13 million, a price-to-earnings ratio of -1.17 and a beta of 2.13.

MacroGenics (NASDAQ:MGNXGet Rating) last released its earnings results on Tuesday, May 3rd. The biopharmaceutical company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.28). MacroGenics had a negative return on equity of 84.52% and a negative net margin of 303.19%. During the same period last year, the firm posted ($0.90) EPS. Equities analysts anticipate that MacroGenics, Inc. will post -3.15 earnings per share for the current year.

A number of research analysts have issued reports on MGNX shares. SVB Leerink decreased their target price on MacroGenics from $40.00 to $23.00 and set an “outperform” rating on the stock in a research report on Friday, February 25th. BMO Capital Markets began coverage on shares of MacroGenics in a research report on Friday, February 11th. They set an “outperform” rating and a $31.00 price objective for the company. Guggenheim cut shares of MacroGenics from a “buy” rating to a “neutral” rating in a research note on Wednesday, May 4th. HC Wainwright dropped their price target on MacroGenics from $41.00 to $35.00 in a research note on Wednesday, May 4th. Finally, Zacks Investment Research upgraded MacroGenics from a “sell” rating to a “hold” rating in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $29.30.

MacroGenics Profile (Get Rating)

MacroGenics, Inc, a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.

Featured Articles

Institutional Ownership by Quarter for MacroGenics (NASDAQ:MGNX)

Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.